We develop immune therapies that support the treatment and prevention of infectious disease and cancer

We develop immune therapies that directly stimulate a powerful immune response in the liver

Our lead programme is targeting a cure for the 250 million patients infected with chronic hepatitis B

Hepatitis B virus infection

Despite the availability of preventative vaccines, 2 billion people worldwide have been infected with hepatitis B virus (HBV). Over 250 million of those infected progress to chronic HBV infection and become susceptible to life threatening liver disease.  Avalia’s therapy aims to provide a necessary cure for these individuals.

Read More
>

Pipeline

Avalia’s immune therapies are designed to target the liver and spleen to modulate a more potent and targeted immune response against certain viruses and cancers. This is achieved by activating a special family of immune cells called natural killer T cells.

Read More
>

News

Worth a shot? The economics of the race for a vaccine

Avalia's CEO Dr Shivali Gulab shares insights into the economics of COVID-19 vaccine development efforts alongside Associate Professor Helen Petousis-Harris, one of the New Zealand’s leading vaccine efficacy and safety experts, based at the University of Auckland.

Read More
>

Initial funding opens doors for national COVID-19 vaccine strategy

New Zealand biotech Avalia Immunotherapies has been awarded bridging funding of $100,000 from the Ministry of Business, Innovation and Employment’s COVID-19 Innovation Acceleration Fund to start work on securing a COVID-19 vaccine for New Zealand, until a national vaccine strategy…

Read More
>

Dr Kronenberg, elected distinguished fellow by AAI

Avalia's newly appointed director, Dr Mitch Kronenberg, receives highest honour for his outstanding scientific contributions to the field of immunology

Read More
>

Key to a Cure

Avalia Immunotherapies could hold the key to a cure for chronic hepatitis B infection—a currently incurable, life-threatening liver disease that affects 250 million patients worldwide.

Read More
>

Harnessing the immune system

Avalia's founding CSO and head of  cancer immunotherapy at Malaghan Institute of Medical Research, Professor Ian Hermans, discusses the developing field of immunotherapy, and how we can use the knowledge gained from understanding the immune system to fight diseases such as…

Read More
>